Lupin And Mark Cuban Shake Hands On Spiriva Alliance In US

Indian Firm Recently Launched First Generic; Aiming For 40%+ Share

Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.

Mark Cuban headshot
Lupin has struck a deal with the Mark Cuban Cost Plus Drug Company • Source: Shutterstock

Only weeks after debuting generic competition in the US to Boehringer Ingelheim’s Spiriva HandiHaler (tiotropium bromide inhalation powder) 18mcg/capsule, Lupin has struck an alliance with the Mark Cuban Cost Plus Drug Company, which the Indian firm hopes will expand availability for the key chronic obstructive pulmonary disease treatment. As part of the move, Lupin has at the same time penned an agreement with Florida-based non-profit the COPD Foundation.

Approved in June this year as the first dry powder inhaler approval from India for the US market, and rolled...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business